Variability of Infectious Aerosols Produced during Coughing by Patients with Pulmonary Tuberculosis

Southeastern National Tuberculosis Center, Emerging Pathogens Institute, Room 257, University of Florida, Gainesville, FL 32610, USA.
American Journal of Respiratory and Critical Care Medicine (Impact Factor: 11.99). 07/2012; 186(5):450-7. DOI: 10.1164/rccm.201203-0444OC
Source: PubMed

ABSTRACT Mycobacterium tuberculosis is transmitted by infectious aerosols, but assessing infectiousness currently relies on sputum microscopy that does not accurately predict the variability in transmission.
To evaluate the feasibility of collecting cough aerosols and the risk factors for infectious aerosol production from patients with pulmonary tuberculosis (TB) in a resource-limited setting.
We enrolled subjects with suspected TB in Kampala, Uganda and collected clinical, radiographic, and microbiological data in addition to cough aerosol cultures. A subset of 38 subjects was studied on 2 or 3 consecutive days to assess reproducibility.
M. tuberculosis was cultured from cough aerosols of 28 of 101 (27.7%; 95% confidence interval [CI], 19.9-37.1%) subjects with culture-confirmed TB, with a median 16 aerosol cfu (range, 1-701) in 10 minutes of coughing. Nearly all (96.4%) cultivable particles were 0.65 to 4.7 μm in size. Positive aerosol cultures were associated with higher Karnofsky performance scores (P = 0.016), higher sputum acid-fast bacilli smear microscopy grades (P = 0.007), lower days to positive in liquid culture (P = 0.004), stronger cough (P = 0.016), and fewer days on TB treatment (P = 0.047). In multivariable analyses, cough aerosol cultures were associated with a salivary/mucosalivary (compared with purulent/mucopurulent) appearance of sputum (odds ratio, 4.42; 95% CI, 1.23-21.43) and low days to positive (per 1-d decrease; odds ratio, 1.17; 95% CI, 1.07-1.33). The within-test (kappa, 0.81; 95% CI, 0.68-0.94) and interday test (kappa, 0.62; 95% CI, 0.43-0.82) reproducibility were high.
A minority of patients with TB (28%) produced culturable cough aerosols. Collection of cough aerosol cultures is feasible and reproducible in a resource-limited setting.

Download full-text


Available from: Scott Dryden-Peterson, Dec 30, 2014
  • Source
    • "A fundamental difference between field efficacy trials and laboratory animal exposure is the number of exposures. It is highly likely that a human infection develops after multiple exposures, probably containing only a few organisms [27]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: There is an urgent need for an improved TB vaccine. Vaccine development is hindered by the lack of immune correlates and uncertain predictive value of preclinical animal models. As data become available from human efficacy trials, there is an opportunity to evaluate the predictive value of the criteria used to select candidate vaccines. Here we review the efficacy in animal models of the MVA85A candidate vaccine in light of recent human efficacy data and propose refinements to the preclinical models with the aim of increasing their predictive value for human efficacy.
    Tuberculosis (Edinburgh, Scotland) 12/2013; 94(2). DOI:10.1016/ · 3.50 Impact Factor
  • Source
    • "Cough-generated aerosols are of particular concern in disease transmission because coughing is a common symptom of respiratory infections and because the violent expulsion of air during a cough generates aerosol particles that can travel two meters or more away from an infected person (Tang et al. 2011; Zhu et al. 2006). Several studies have shown that people expel aerosol particles containing potentially infectious microorganisms during coughing, speaking, or breathing (Fabian et al. 2008; Fennelly et al. 2012; Lindsley et al. 2010; Morawska et al. 2009; Stelzer-Braid et al. 2009), but the dispersion of cough aerosols into the environment and their capacity for spreading microorganisms are not well understood (Morawska 2006). In addition, the relative importance of respiratory aerosols in the transmission of illness is often unclear and disputed (Goldmann 2001; Musher 2003; Tellier 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Aerosol particles expelled during human coughs are a potential pathway for infectious disease transmission. However, the importance of airborne transmission is unclear for many diseases. To better understand the role of cough aerosol particles in the spread of disease and the efficacy of different types of protective measures, we constructed a cough aerosol simulator that produces a human-like cough in a controlled environment. The simulated cough has a 4.2 l volume and is based on coughs recorded from influenza patients. In one configuration, the simulator produces a cough aerosol containing particles from 0.1 to 100 μm in diameter with a volume median diameter (VMD) of 8.5 μm and a geometric standard deviation (GSD) of 2.9. In a second configuration, the cough aerosol has a size range of 0.1–30 μm, a VMD of 3.4 μm, and a GSD of 2.3. The total aerosol volume expelled during each cough is 68 μl. By generating a controlled and reproducible artificial cough, the simulator allows us to test different ventilation, disinfection, and personal protection scenarios. The system can be used with live pathogens, including influenza virus, which allows isolation precautions used in the healthcare field to be tested without risk of exposure for workers or patients. The information gained from tests with the simulator will help to better understand the transmission of infectious diseases, develop improved techniques for infection control, and improve safety for healthcare workers and patients.Copyright 2013 American Association for Aerosol Research
    Aerosol Science and Technology 08/2013; 47(8). DOI:10.1080/02786826.2013.803019 · 3.16 Impact Factor
  • Source
    • "A major source of uncertainty is the unknown size distribution and the rate of release of droplets containing infectious viruses from infected persons. Infectious aerosol collection during respiratory maneuvers has previously been studied to a limited degree (Fennelly et al. 2004; Fabian et al. 2008; Lindsley et al. 2010; Fennelly et al. 2012). In pulmonary tuberculosis patients, Fennelly et al. (2004) used the Cough Aerosol Sampling System (CASS) to measure respirable, infectious mycobacterial aerosols and demonstrated that quantification of cough-generated aerosols was feasible. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The importance of the aerosol mode for transmission of influenza is unknown. Understanding the role of aerosols is essential to developing public health interventions such as the use of surgical masks as a source control to prevent the release of infectious aerosols. Little information is available on the number and size of particles generated by infected persons, which is partly due to the limitations of conventional air samplers, which do not efficiently capture fine particles or maintain microorganism viability. We designed and built a new sampler, called the G-II, that collects exhaled breath particles that can be used in infectivity analyses. The G-II allows test subjects to perform various respiratory maneuvers (i.e. tidal breathing, coughing, and talking) and allows subjects to wear a mask or respirator during testing. A conventional slit impactor collects particles > 5.0 μm. Condensation of water vapor is used to grow remaining particles, including fine particles, to a size large enough to be efficiently collected by a 1.0 μm slit impactor and be deposited into a buffer-containing collector. We evaluated the G-II for fine particle collection efficiency with inert particle aerosols and evaluated infective virus collection using influenza A virus aerosols. Testing results showed greater than 85% collection efficiency for particles greater than 50nm and influenza virus collection comparable with a reference SKC BioSampler®. The new design will enable determination of exhaled infectious virus generation rate and evaluate control strategies such as wearing a surgical type mask to prevent the release of viruses from infected persons.
    Aerosol Science and Technology 04/2013; 47(4):444-451. DOI:10.1080/02786826.2012.762973 · 3.16 Impact Factor
Show more